Home » Stocks » Bio-Techne

Bio-Techne Corp (TECH)

Stock Price: $268.46 USD -1.20 (-0.45%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 10.35B
Revenue (ttm) 738.69M
Net Income (ttm) 229.30M
Shares Out 38.56M
EPS (ttm) 5.82
PE Ratio 46.13
Forward PE 52.36
Dividend $1.28
Dividend Yield 0.48%

Stock Quote

Trading Day Oct 23, 2020
Last Price $268.46
Previous Close $269.66
Change ($) -1.20
Change (%) -0.45%
Day's Open 270.98
Day's Range 266.60 - 271.19
Day's Volume 126,628
52-Week Range 155.17 - 286.68

More Stats

Market Cap 10.35B
Enterprise Value 10.51B
Earnings Date (est) Nov 3, 2020
Ex-Dividend Date Aug 17, 2020
Shares Outstanding 38.56M
Float 38.07M
EPS (basic) 6.00
EPS (diluted) 5.82
FCF / Share 4.02
Dividend $1.28
Dividend Yield 0.48%
Earnings Yield 2.17%
FCF Yield 1.48%
Payout Ratio 21.30%
Shares Short 585,113
Short Ratio 3.12
Short % of Float 1.54%
Beta 0.98
PE Ratio 46.13
Forward PE 52.36
P/FCF Ratio 67.44
PS Ratio 14.01
PB Ratio 7.49
Revenue 738.69M
Operating Income 157.42M
Net Income 229.30M
Free Cash Flow 153.47M
Net Cash -162.63M
Net Cash / Share -4.22
Gross Margin 65.41%
Operating Margin 21.31%
Profit Margin 31.00%
FCF Margin 20.78%
ROA 4.82%
ROE 18.01%
ROIC 30.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 4
Overweight 2
Hold 4
Underweight 1
Sell 0

Analyst Consensus: Overweight

Price Target

$299.33*
(11.50% upside)
Low
265
Current: $268.46
High
365
Target: 299.33
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2020201920182017201620152014201320122011
Revenue739714643563499452358311315290
Revenue Growth3.46%11.04%14.21%12.82%10.34%26.41%15.19%-1.27%8.48%-
Gross Profit483473432375337307251231236225
Operating Income157147136121151147160158166163
Net Income22996.0712676.09104108111113112112
Shares Outstanding38.2037.7837.4837.3137.1937.1036.8936.8436.9437.10
Earnings Per Share5.822.473.312.032.802.893.003.053.043.02
EPS Growth135.63%-25.38%63.05%-27.5%-3.11%-3.67%-1.64%0.33%0.66%-
Dividend Per Share1.281.281.281.281.281.271.231.181.111.07
Dividend Growth0%0%0%0%0.79%3.25%4.24%6.31%3.74%-
Operating Cash Flow205182170144144139137124127127
Capital Expenditures-51.74-25.41-20.93-15.18-16.90-19.91-13.82-22.45-6.02-3.63
Free Cash Flow153156149129127119123101121124
Cash & Equivalents27116618215895.84111363333269141
Total Debt43450533934495.2677.0212.95---
Net Cash / Debt-163-339-157-1860.5833.90350333269141
Assets2,0281,8841,5931,5581,1301,063862778719618
Liabilities64671951460925021667.2340.5644.8831.55
Book Value1,3811,1661,079950879847795738674586
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Bio-Techne Corp
Country United States
Employees 2,300
CEO Charles R. Kummeth

Stock Information

Ticker Symbol TECH
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TECH
IPO Date February 9, 1989

Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.